Last reviewed · How we verify

resorcinol

unknown active Under review

resorcinol is a drug. It is currently in unknown development for Acne vulgaris, Acneiform eruption, Itching of skin.

Resorcinol is a small molecule organic compound with the formula C6H4(OH)2, classified as a phenolic compound and one of three isomeric benzenediols. It is used in a 0.2% concentration in a cream as an intervention in clinical trials for conditions such as wrinkles, facial hyperpigmentation, melasma, and hydradenitis.

At a glance

Generic nameresorcinol
TargetCarbonic anhydrase 12, Carbonic anhydrase 14, Carbonic anhydrase 2
Therapeutic areaPain
Phaseunknown

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about resorcinol

What is resorcinol?

resorcinol is a pharmaceutical drug, indicated for Acne vulgaris, Acneiform eruption, Itching of skin.

What is resorcinol used for?

resorcinol is indicated for Acne vulgaris, Acneiform eruption, Itching of skin, Minor Skin Wound Pain, Skin irritation.

What development phase is resorcinol in?

resorcinol is in unknown.

What does resorcinol target?

resorcinol targets Carbonic anhydrase 12, Carbonic anhydrase 14, Carbonic anhydrase 2.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing